Project Grant R44AI186534
Award Date
7/2/24
Completion Date
6/30/26
Dollars Obligated
$1.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Trethera Corp (QB66ZMAUF5P7)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Van Nuys, CA 91423, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 - Allergy and Infectious Diseases Research, is focused on developing novel tools for precision targeting of pro-autoimmune Th17 cells. The $166,000 award supports the establishment of a high-throughput drug screening pipeline to identify selective inhibitors of pro-autoimmune Th17 cells, as well as the generation of biotinylated clofazimine to identify its molecular...
This federal Project Grant award of $417,984 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research conducted by the Scripps Research Institute to identify small molecule compounds that can selectively induce the differentiation of functional regulatory T cells (Tregs). The research aims to address challenges in expanding Treg populations without causing unintended...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Emmune Inc. to conduct pre-clinical IND-enabling studies for ECD4-IG, a long-acting recombinant protein therapeutic for HIV. The award will support in vitro assays, a pre-IND meeting with the FDA, and a definitive GLP toxicology study in macaques to assess safety and toxicity, in preparation for a Phase 1...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to develop a bifunctional IgE antagonist and dissociator (ANDI) drug for treating severe allergic asthma. The $320,863 award to Aaiit LLC aims to advance ANDI, a novel protein-based therapeutic that can both antagonize and dissociate IgE bound to mast cell receptors. This is intended to complement the existing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...
This Cooperative Agreement award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $595,834 to Trellis Bioscience, Inc. to conduct a Phase 1 safety trial for TRL1068, an inhaled therapeutic monoclonal antibody targeting bacterial pneumonia. The award will support the development of TRL1068 as a novel treatment to disrupt bacterial biofilms and enhance the effectiveness of conventional...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Cellergy Pharma Inc. in Wilmington, Delaware. The goal of this 2-year project is to develop an innovative antibody drug that can efficiently and specifically kill IgE-producing B cells to achieve complete and durable suppression of allergy symptoms without significant side effects. The funded research will determine the...
This federal Project Grant award of $787,171 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop novel 1,2,4-triazole and pyrrolidine compounds as potential treatments for tuberculosis (TB). The primary objectives are to demonstrate preclinical proof-of-concept for these compound classes, optimize their pharmacological properties, and investigate their unique mechanism of action compared...
This Project Grant award, valued at $499,746.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA Program 93.855 - Allergy and Infectious Diseases Research. The award supports research to uncover the genetic basis and molecular mechanisms underlying the propensity of T cells towards autoimmunity. Key focus areas include: Elucidating the role of mitochondrial cristae integrity and oxidative stress in regulating effector T cell functions and...